We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Algeta Announces first US Patient Randomized in ALSYMPCA Phase III Study

News   Dec 16, 2009

 
Algeta Announces first US Patient Randomized in ALSYMPCA Phase III Study
 
 
 

RELATED ARTICLES

Neurofilament Light Change Dynamics: Alzheimer's Diagnostics Progress

News

A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer’s disease – even before they show signs of confusion and memory loss, according to a new study from Washington University School of Medicine in St. Louis and the German Center for Neurodegenerative Diseases in Germany.

READ MORE

Placental Mitochondria Adapt When Mothers Have Poor Diets or Low Oxygen

News

Using mice to model conditions in the womb, Cambridge researchers have provided new insights on how the placenta regulates how much oxygen and nutrients it transports to babies during challenging pregnancies.

READ MORE

Infrared to Visible Light: A Novel Route to Photodynamic Therapy & Drug Development

News

Researchers have succeeded in developing a chemical process to absorb infrared light and re-emit it as visible energy, allowing innocuous radiation to penetrate living tissue and other materials without the damage caused by high-intensity light exposure.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE